Published in AIDS Weekly, February 19th, 1996
Viramune is an investigational drug that belongs to a new class of anti-retroviral compounds called non-nucleoside reverse transcriptase inhibitors. The target date for commencement of the expanded access program is in March 1996, after finalizing the protocol with the U.S. Food and Drug Administration (FDA).
The major criteria for inclusion in the program include: male or female patients over 13 years of age with HIV-1 infection and a CD4+ cell count at or below 50. ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.